anti-CD123 antigen-armed antibody

Anti-CD123 antigen-armed antibody (AgAb) is an experimental immunotherapy designed for the treatment of acute myeloid leukemia (AML). Developed at the German Cancer Research Center (DKFZ), this modality consists of a monoclonal antibody targeting the CD123 antigen (interleukin-3 receptor alpha chain) fused to immunodominant epitopes from the Epstein-Barr virus (EBV). Upon binding to CD123 on the surface of AML blasts, the AgAb is internalized via receptor-mediated endocytosis. The viral epitopes are then processed and presented on the cell surface via MHC class II molecules. This presentation allows circulating EBV-specific memory CD4+ T cells, present in the majority of the human population, to recognize the AML cells as virally infected and mediate direct lysis and bystander killing. This strategy aims to redirect potent anti-viral immunity toward cancer cells that otherwise exhibit low basal immunogenicity.

Other names

CD123-AgAbCD-123-AgAbCD 123-AgAbanti-CD123 AgAbanti-CD-123 AgAbanti-CD 123 AgAb